I believe hgen and rlftf? Are still going after severe. Not sure any big pharmas have had any success in that area. Gilead, Eli lilly and regn all lean towards m/m which we were told are unimportant. Well at least mild, we could do a moderate trial but I think we should target longhaulers first. Moderate might get big pharma crowded but none of them are trying long haulers or have severe yet. We may have those locked up.

I think hgen had an interim with a continuation recommendation, so they might be promising. Not sure about relief therapeutics inhaler. Only hearing anecdotal, don't really follow either closely. Mostly because I'm not chasing covid bubble stocks. I'm in cydy for the plethora of indications and staying away from stocks that were nothing until covid hit. Money can certainly be made there, day trading just isn't my style these days.